Moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post‐hoc analysis of the RACING trial
Primary result · Composite of CV death, major CV events, or non-fatal stroke (MetS)Result — go to the resultHazard ratio 0.97 95% CI 0.72–1.32Authors' conclusion
In patients with MetS and atherosclerotic cardiovascular disease, a moderate-intensity statin with ezetimibe combination therapy had comparable cardiovascular benefits with those of high-intensity statin monotherapy. Meanwhile, ezetimibe combination therapy was associated with lower drug intolerance and low-density lipoprotein cholesterol levels, but there was no apparent between-group difference in new-onset diabetes.
Study context
- Population
- Patients with metabolic syndrome (MetS; ≥3 of 5 criteria) and atherosclerotic CVD in the RACING trialMetS
- Participants
- 1,703 patients
- Comparison
- Moderate-intensity statin with ezetimibe vs high-intensity statin monotherapy
- Primary endpoint
- Composite of:
- Cardiovascular death
- Major cardiovascular events
- Non-fatal stroke
- Follow-up
- 3 years
Primary result
As reported in the abstract
- CV death
- Major CV events
- Non-fatal stroke (MetS)
Hazard ratio
0.97
95% CI 0.72–1.32
P = 0.868
By group
Further findings
LDL-C level
P < 0.001
Interaction between MetS and therapy
- No significant interactions between MetS and therapy regarding study outcomes in the total population
Safety
Intolerance-related drug discontinuation or dose reduction
P < 0.001
New-onset diabetes
P = 0.822
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →